Nanomedicinal strategies as efficient therapeutic interventions for delivery of cancer vaccines

Beg, Sarwar; Kawish, S.M.; Panda, Santosh Kumar; Tarique, Mohammed; Malik, Arshi; Afaq, Sarah; Alsamghan, Awad S.; Iqbal, Jawed; Alam, Kainat; Rahman, Mahfoozur

doi:10.1016/j.semcancer.2019.10.005

Cited by 27 publications

(10 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanomedicines encompass various nanocarriers with sizes ranging between 10 nm and 1000 nm. They are highly useful owing to their small size and particle dimension, high aspect ratio, encapsulation ability, and the opportunity to functionalize the surface to deliver loaded cargos, including plasmid DNA, small interfering RNA and mRNA [44][45][46]. Herein, we generated CS/ si-circPAK1 nanocomplexes with Chitosan material to simulate gene-targeted therapy.…”

Section: Discussionmentioning

confidence: 99%

CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ

Hao

Zhang

Shi

et al. 2022

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Background Circular RNA (circRNA), a new class of non-coding RNA, has obvious correlations with the occurrence and development of many diseases, including tumors. This study aimed to investigate the potential roles of circPAK1 in hepatocellular carcinoma (HCC). Methods High-throughput sequencing was performed on 3 pairs of HCC and matched normal tissues to determine the upregulated circRNAs. The expression level of circPAK1 was detected by qRT-PCR in HCC and paired with normal liver tissue samples. The effects of circPAK1 on proliferation, invasion, metastasis and apoptosis of HCC cells were evaluated by in vitro and in vivo experiments. We also constructed Chitosan/si-circPAK1 (CS/si-circPAK1) nanocomplexes using Chitosan material to evaluate its in vivo therapeutic effect on HCC. High-throughput sequencing, RNA-sequencing, RNA probe pull-down, RNA immunoprecipitation and Co-Immunoprecipitation assays were performed to explore the relationship between circPAK1, 14–3-3ζ, p-LATS1 and YAP. Exosomes isolated from lenvatinib-resistant HCC cell lines were used to evaluate the relationship between exosomal circPAK1 and lenvatinib resistance. Results CircPAK1, a novel circRNA, is highly expressed in HCC tumor tissues and cell lines as well as correlated with poor outcomes in HCC patients. Functionally, circPAK1 knockdown inhibited HCC cell proliferation, migration, invasion and angiogenesis while circPAK1 overexpression promoted HCC progression. The tumor-promoting phenotypes of circPAK1 on HCC were also confirmed by animal experiments. Importantly, the application of CS/si-circPAK1 nanocomplexes showed a better therapeutic effect on tumor growth and metastasis. Mechanistically, circPAK1 enhanced HCC progression by inactivating the Hippo signaling pathway, and this kind of inactivation is based on its competitively binding of 14–3-3 ζ with YAP, which weakens the recruitment and cytoplasmic fixation of 14–3-3 ζ to YAP, thus promoting YAP nucleus localization. Additionally, circPAK1 could be transported by exosomes from lenvatinib-resistant cells to sensitive cells and induce lenvatinib resistance of receipt cells. Conclusion CircPAK1 exerts its oncogenic function by competitively binding 14–3-3 ζ with YAP, thus promoting YAP nucleus localization, leading to the inactivation of a Hippo signaling pathway. Exosomal circPAK1 may drive resistance to lenvatinib, providing a potential therapeutic target for HCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ

Hao

Zhang

Shi

et al. 2022

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…However, BRU is associated with a number of toxic adverse effects (10-16), which may limit its application in the clinical setting. Nanocarriers are promising systems for the effective treatment of cancer (36,37). As mentioned above, glycosaminoglycan plCSA is specifically expressed in most cancer cells and placental trophoblasts.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, plcSA-NPs may be used in targeted therapy of human tumor cells. Thus, it was hypothesized that encapsulating BRU in plCSA-modified NPs would prevent its inherent side effects (36). In the present study, plcSA-BP-conjugated lipid-polymer NPs loaded with BRU (plcSA-BNPs) were synthesized.…”

Section: Discussionmentioning

confidence: 99%

Inhibitory effects of brusatol delivered using glycosaminoglycan‑placental chondroitin sulfate A‑modified nanoparticles on the proliferation, migration and invasion of cancer cells

et al. 2020

View full text Add to dashboard Cite

Breakthroughs in cancer management result from the development of drugs that can be used for early diagnosis and effective treatment. Surgery, chemotherapy, radiotherapy and hormone therapy are the main anticancer therapies. However, traditional cancer chemotherapy is associated with serious systemic side effects. Nanoparticles (NPs) provide an effective solution for cancer treatment via the targeted delivery of drugs to cancer cells, while minimizing injury to normal cells. Glycosaminoglycan-placental chondroitin sulfate A (plcSA) is expressed in a number of tumor cells and trophoblasts. A plcSA-binding peptide (plcSA-BP) was isolated from malaria protein VAR2cSA, which can effectively promote the binding of lipid polymer NPs to tumor cells, thereby significantly enhancing the anticancer effect of encapsulated drugs. Brusatol is an important compound derived from Brucea javanica that exerts a multitude of biological effects, including inhibiting tumor cell growth, reducing the reproduction of malaria parasites, reducing inflammation and resisting virus invasion. In the present study, brusatol-loaded NPs (BNPs) or coumarin 6 NPs (cNPs), plcSA-BP and scrambled control peptide-bound BNPs or cNPs were prepared. Ovarian cancer cells (SKOV3), endometrial cancer cells (HEc-1-A) and lung cancer cells (A549) were treated with the NPs. The uptake of plcSA-cNPs by tumor cells was found to be markedly higher compared with that of other types of NPs. Further studies demonstrated that the plcSA-BNPs promoted the apoptosis of cancer cells more effectively and inhibited their proliferation, invasion and migration, accompanied by downregulation of matrix metalloproteinase (MMP)-2, MMP-9 and B-cell cLL/lymphoma 2 (BcL2) levels, but upregulation of BcL2-associated X protein BAX and cleaved caspase-3 levels. The results demonstrated the potential of brusatol delivered by plCSA-modified NPs as a chemotherapeutic agent for the targeted therapy of tumors by regulating the BcL2, BAX, cleaved caspase-3, MMP-2 and MMP-9 pathways, and indicated that it may be an effective and safe strategy for the treatment of various tumors.

show abstract

“…Therapeutic energy-depositing devices such as photothermal/photodynamic therapy (PTT), alternating magnetic field (AMF), focused ultrasound (FUS), radiowave therapy or widely used ionizing radiation therapy can serve as an external modes of inducing immunogenic cell death, making them a potential part of ISU with NPs [91,92,[130][131][132]. The NPs-ISVs can also mediate the effects of external energy deposition into the solid tumor to increase the overall ISV immune response.…”

Section: Combination Of Energy Depositing/hyperthermia Devices With Nmentioning

confidence: 99%

Using nanoparticles forin situvaccination against cancer: mechanisms and immunotherapy benefits

Gorbet

Singh

Mao

et al. 2020

International Journal of Hyperthermia

View full text Add to dashboard Cite

Nanomedicinal strategies as efficient therapeutic interventions for delivery of cancer vaccines

Cited by 27 publications

References 89 publications

CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ

CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ

Inhibitory effects of brusatol delivered using glycosaminoglycan‑placental chondroitin sulfate A‑modified nanoparticles on the proliferation, migration and invasion of cancer cells

Using nanoparticles forin situvaccination against cancer: mechanisms and immunotherapy benefits

Contact Info

Product

Resources

About